title: Pure white cell aplasia induced by mesalazine in a patient with ulcerative colitis.
abstract: Objectives and importance: Mesalazine is a widely used and generally safe drug for the treatment of chronic inflammatory bowel diseases. Neutropenia rarely complicates this treatment and very few cases have been reported in the literature.
  
  
  METHODS
  We report here the case of a patient with ulcerative colitis who developed a severe febrile neutropenia during treatment with mesalazine.
  
  
  METHODS
  Drug withdrawal and treatment with granulocyte colony-stimulating factor resulted in a complete and durable remission of cytopenia. Conclusion headings: We recommend periodic blood count monitoring in all patients undergoing treatment with mesalazine.
authors: Department of Hematology and Transfusion Medicine, Azienda Ospedaliera, Mantova, Italy. francesco.frattini@aopoma.it
authors: Francesco
authors: F
authors: Frattini
authors: Silvia
authors: S
authors: Crestani
authors: Pier Paolo
authors: PP
authors: Vescovi
authors: Massimo
authors: M
authors: Franchini
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D064146:Chemotherapy-Induced Febrile Neutropenia / Q000188:drug therapy / Q000209:etiology*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D057915:Drug Substitution; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D019804:Mesalamine / Q000009:adverse effects*; D008875:Middle Aged
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016179:Granulocyte Colony-Stimulating Factor; D019804:Mesalamine